2024
Clinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma, and a History of Nasal Polyps From the NAVIGATOR Study
Lugogo N, Peters A, Chupp G, Wechsler M, Caveney S, Martin N, Parikh B, Ambrose C. Clinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma, and a History of Nasal Polyps From the NAVIGATOR Study. 2024, a5251-a5251. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5251.Peer-Reviewed Original Research
2023
Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlacebo
2021
Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Sousa A, Martin N, Yang S, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal Polyps. 2021, a1344-a1344. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1344.Peer-Reviewed Original Research